Graeme F. Nixon

Graeme F. Nixon

Auto-generated profile, based on publicly available information

Graeme F. Nixon

School of Medical Sciences, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 October 2009 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
GNGraeme F. Nixon
Graeme F. Nixon
Sphingolipids are formed via the metabolism of sphingomyelin, a constituent of the plasma membrane, or by de novo synthesis. Enzymatic pathways result in the formation of several different lipid mediators, which are known to have important roles in many cellular processes, including proliferation, apoptosis and migration. Several studies now suggest that these sphingolipid mediators, including ceramide, ceramide 1‐phosphate and sphingosine 1‐phosphate (S1P), are likely to have an integral role in inflammation. This can involve, for example, activation of pro‐inflammatory transcription factors in different cell types and induction of cyclooxygenase‐2, leading to production of pro‐inflammatory prostaglandins. The mode of action of each sphingolipid is different. Increased ceramide production leads to the formation of ceramide‐rich areas of the membrane, which may assemble signalling complexes, whereas S1P acts via high‐affinity G‐protein‐coupled S1P receptors on the plasma membrane. Recent studies have demonstrated that in vitro effects of sphingolipids on inflammation can translate into in vivo models. This review will highlight the areas of research where sphingolipids are involved in inflammation and the mechanisms of action of each mediator. In addition, the therapeutic potential of drugs that alter sphingolipid actions will be examined with reference to disease states, such as asthma and inflammatory bowel disease, which involve important inflammatory components. A significant body of research now indicates that sphingolipids are intimately involved in the inflammatory process and recent studies have demonstrated that these lipids, together with associated enzymes and receptors, can provide effective drug targets for the treatment of pathological inflammation.This article is part of a themed issue on Mediators and Receptors in the Resolution of Inflammation. To view this issue visit http://www3.interscience.wiley.com/journal/121548564/issueyear?year=2009

1 December 1994 in Journal of Muscle Research and Cell Motility
Verified
Journal Article
Closed access
PDF file
GNGraeme F. Nixon
Graeme F. Nixon
GMGregory A. Mignery
Gregory A. Mignery
ASAvril V. Somlyo
Avril V. Somlyo

26 July 2002 in Circulation Research
Verified
Journal Article
Closed access
FCFrederic Coussin
Frederic Coussin
RSRoderick H. Scott
Roderick H. Scott
AWAlan Wise
Alan Wise
GNGraeme F. Nixon
Graeme F. Nixon
Sphingosine 1-phosphate (S1P), a lipid released from activated platelets, influences physiological processes in the cardiovascular system via activation of the endothelial differentiation gene (EDG/S1P) family of 7 transmembrane G protein–coupled receptors. In cultured vascular smooth muscle (VSM) cells, S1P signaling has been shown to stimulate proliferative responses; however, its role in vasoconstriction has not been examined. In the present study, the effects of S1P and EDG/S1P receptor expression were determined in rat VSM from cerebral artery and aorta. S1P induced constriction of cerebral artery, which was partly dependent on activation of p160 ROCK (Rho-kinase). S1P also induced activation of RhoA in cerebral artery with a similar time course to contraction. In aorta, S1P did not produce a constriction or RhoA activation. In VSM myocytes from cerebral arteries, stimulation with S1P gives rise to a global increase in [Ca 2+ ] i , initially generated via Ca 2+ release from the sarcoplasmic reticulum by an inositol 1,4,5-trisphosphate–dependent pathway. In aorta VSM, a small increase in [Ca 2+ ] i was observed after stimulation at higher concentrations of S1P. S1P induced activation of p42/p44 mapk in aorta and cerebral artery VSM. Subtype-specific S1P receptor antibodies revealed that the expression of S1P 3 /EDG-3 and S1P 2 /EDG-5 receptors is 4-fold higher in cerebral artery compared with aorta. S1P 1 /EDG-1 receptor expression was similar in both types of VSM. Therefore, the ability of S1P to act as a vasoactive mediator is dependent on the activation of associated signaling pathways and may vary in different VSM. This differential signaling may be related to the expression of S1P receptor subtypes.

1 August 2008 in Cell Calcium
Verified
Journal Article
Closed access
NKNicholas P. Kinnear
Nicholas P. Kinnear
CWChristopher N. Wyatt
Christopher N. Wyatt
JCJill H. Clark
Jill H. Clark
PCPeter J. Calcraft
Peter J. Calcraft
SFSidney Fleischer
Sidney Fleischer
AEA. Mark Evans
A. Mark Evans

1 March 2003 in Molecular Pharmacology
Verified
Journal Article
Open access
PDF file
IHIrene Hunter
Irene Hunter
HCHannah J. Cobban
Hannah J. Cobban
PVPeter Vandenabeele
Peter Vandenabeele
DMDavid J. MacEwan
David J. MacEwan
GNGraeme F. Nixon
Graeme F. Nixon
Tumor necrosis factor-α (TNF), an inflammatory cytokine, has a potentially important role in the pathogenesis of bronchial asthma and may contribute to airway hyper-responsiveness. Recent evidence has revealed that TNF can increase the Ca2+ sensitivity of agonist-stimulated myosin light chain20 (MLC20) phosphorylation and contractility in guinea pig airway smooth muscle (ASM). In the present study, the potential intracellular pathways responsible for this TNF-induced Ca2+ sensitization were investigated. In permeabilized cultured guinea pig ASM cells, recombinant human TNF stimulated an increase in Ca2+-activated MLC20 phosphorylation under Ca2+ “clamp” conditions. This increased MLC20 phosphorylation was inhibited by preincubation with the Rho-kinase inhibitor Y27632. TNF also increased the proportion of GTP-bound RhoA, as measured using rhotekin Rho-binding domain, in a time course compatible with a role in the TNF-induced Ca2+sensitization. In cultured human ASM cells, recombinant human TNF also activated RhoA with a similar time course. In addition, TNF stimulated phosphorylation of the regulatory subunit of the myosin phosphatase, which was inhibited by Y27632. Although human ASM cells expressed both receptor subtypes, TNF-R1 and TNF-R2, the activation of RhoA was predominantly via stimulation of the TNF-R1, although RhoA did not immunoprecipitate with the TNF-R1. In conclusion, the TNF-induced increase in the Ca2+ sensitivity of MLC20phosphorylation is through stimulation of the TNF-R1 receptor and via a RhoA/Rho-kinase pathway leading to inhibition of the myosin light chain phosphatase. This intracellular mechanism may contribute to TNF-induced airway hyper-responsiveness.

1 January 2008 in Progress in Lipid Research
Verified
Journal Article
Closed access
GNGraeme F. Nixon
Graeme F. Nixon
FMFiona A. Mathieson
Fiona A. Mathieson
IHIrene Hunter
Irene Hunter